Imaflex Management

Mr. Stephan Yazedjian, CA, is President & CEO of Imaflex Inc. from October 28, 2024. Mr. Yazedjian previously worked as Chief Financial Officer at Fantuan, Chief of staff &Advisor to the COO at Reinsurance...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Joseph Abbandonato	Executive Chairman	26.1yrs	CA$154.91k	27.78% CA$ 21.0m
Robert Therrien	Head of Finance	1.8yrs	CA$33.85k	no data
Tony Abbandonato	VP of Sales	31.8yrs	CA$205.28k	3.86% CA$ 2.9m
Ralf Dujardin	Vice President of Marketing & Innovation	11.3yrs	CA$230.19k	0.83% CA$ 629.0k
Stephan Yazedjian	President & CEO	less than a year	no data	no data

1.8yrs

Average Tenure

Experienced Management: IFX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Joseph Abbandonato	Executive Chairman	26.1yrs	CA$154.91k	27.78% CA$ 21.0m
Tony Abbandonato	VP of Sales	8.4yrs	CA$205.28k	3.86% CA$ 2.9m
Michel Baril	Independent Director	16.7yrs	CA$8.00k	0.13% CA$ 101.5k
Roberto Longo	Independent Director	2.6yrs	CA$9.00k	0.0096% CA$ 7.3k
Philip Nolan	Independent Director	23.4yrs	CA$8.00k	9.29% CA$ 7.0m
Consolato Gattuso	Independent Director	12.7yrs	CA$8.00k	0.18% CA$ 138.2k
Lorne Steinberg	Independent Director	7.4yrs	CA$8.00k	0.19% CA$ 145.0k

12.7yrs

Average Tenure

Experienced Board: IFX's board of directors are seasoned and experienced ( 12.7 years average tenure).

Imaflex Management

Management criteria checks 1/4

Key information

Recent management updates

Insider recently sold CA$59k worth of stock

Imaflex Inc. Announces CEO Changes, Effective October 28, 2024

Insufficient new directors

Imaflex Inc., Annual General Meeting, Jun 13, 2024

Insider recently sold CA$67k worth of stock

Imaflex Inc. Announces CEO Changes

Recent updates

Insider recently sold CA$59k worth of stock

Imaflex Inc. Announces CEO Changes, Effective October 28, 2024

Second quarter 2024 earnings released: EPS: CA$0.07 (vs CA$0.008 in 2Q 2023)

Imaflex (CVE:IFX) Is Reinvesting At Lower Rates Of Return

Market Might Still Lack Some Conviction On Imaflex Inc. (CVE:IFX) Even After 28% Share Price Boost

Investor sentiment improves as stock rises 24%

Revenues Not Telling The Story For Imaflex Inc. (CVE:IFX) After Shares Rise 48%

Investor sentiment improves as stock rises 18%

There May Be Some Bright Spots In Imaflex's (CVE:IFX) Earnings

First quarter 2024 earnings released: EPS: CA$0.04 (vs CA$0.018 in 1Q 2023)

Insufficient new directors

Full year 2023 earnings released: EPS: CA$0.01 (vs CA$0.18 in FY 2022)

Imaflex Inc., Annual General Meeting, Jun 13, 2024

Imaflex (CVE:IFX) Might Be Having Difficulty Using Its Capital Effectively

Third quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.06 in 3Q 2022)

Is Imaflex (CVE:IFX) A Risky Investment?

Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.066 in 2Q 2022)

Investor sentiment deteriorates as stock falls 18%

Insider recently sold CA$67k worth of stock

Imaflex Inc. Announces CEO Changes

Imaflex Inc. Appoints Roger Tambay as CEO

First quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.04 in 1Q 2022)

Imaflex Inc. Announces Chief Financial Officer Changes

Does Imaflex (CVE:IFX) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: CA$0.18 (vs CA$0.17 in FY 2021)

We Think Imaflex (CVE:IFX) Can Stay On Top Of Its Debt

Third quarter 2022 earnings released: EPS: CA$0.06 (vs CA$0.055 in 3Q 2021)

Imaflex Inc. Provides Earnings Guidance for the Full Year 2022

Price target increased to CA$1.95

Insufficient new directors

Imaflex Inc. Submits Advaseal® Registration Package to the EPA

Does Imaflex (CVE:IFX) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: EPS: CA$0.07 (vs CA$0.04 in 2Q 2021)

VP of Manufacturing recently sold CA$56k worth of stock

First quarter 2022 earnings released: EPS: CA$0.04 (vs CA$0.039 in 1Q 2021)

Is It Too Late To Consider Buying Imaflex Inc. (CVE:IFX)?

Price target increased to CA$1.95

Insufficient new directors

Imaflex Inc. Provides Earnings Guidance for the First Quarter 2022

Full year 2021 earnings released: EPS: CA$0.17 (vs CA$0.13 in FY 2020)

Imaflex Inc., Annual General Meeting, Jun 16, 2022

Imaflex Inc. Appoints Roberto Longo as Director, Chair the Audit Committee

Imaflex Inc. Announces Resignation of Mario Settino as Director

Vice-President of Corporate Affairs recently sold CA$56k worth of stock

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Imaflex (CVE:IFX) Could Easily Take On More Debt

Insider recently sold CA$520k worth of stock

VP of Manufacturing recently sold CA$98k worth of stock

Insider exercised options to buy CA$540k worth of stock.

Investors Should Be Encouraged By Imaflex's (CVE:IFX) Returns On Capital

Vice-President of Corporate Affairs exercised options to buy CA$735k worth of stock.

Second quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.007 in 2Q 2020)

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imaflex Inc.'s (CVE:IFX) CEO For Now

Imaflex (CVE:IFX) Seems To Use Debt Rather Sparingly

First quarter 2021 earnings released: EPS CA$0.039 (vs CA$0.062 in 1Q 2020)

Here's Why I Think Imaflex (CVE:IFX) Might Deserve Your Attention Today

Full year 2020 earnings released: EPS CA$0.13 (vs CA$0.031 in FY 2019)

Investor sentiment improved over the past week

Imaflex (CVE:IFX) Shareholders Will Want The ROCE Trajectory To Continue

Did Imaflex Inc. (CVE:IFX) Insiders Sell Shares?

Is Imaflex Inc.'s (CVE:IFX) Latest Stock Performance A Reflection Of Its Financial Health?

Imaflex Announces Positive Independent Results for the ADVASEAL Release Study

New 90-day high: CA$1.22

Is Imaflex (CVE:IFX) A Risky Investment?

What We Make Of Imaflex's (CVE:IFX) Returns On Capital

Imaflex (CVE:IFX) Is Growing Earnings But Are They A Good Guide?

Have Insiders Sold Imaflex Inc. (CVE:IFX) Shares Recently?

Insider recently sold CA$108k worth of stock

Revenue beats expectations